Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5)

Autor: Cillo, U, De Carlis, L, Del Gaudio, M, De Simone, P, Fagiuoli, S, Lupo, F, Tisone, G, Volpes, R, Avolio, A, Bitetto, D, Boccagni, P, Carraro, A, Castellaneta, A, Colledan, M, De Maria, N, Di Benedetto, F, Lanza, Ag, Gardini, I, Guglielmo, N, Invernizzi, F, Laurenzi, A, Leandro, G, Lenci, I, Lorenzin, D, Mameli, L, Manzia, Tm, Mariani, A, Mennini, G, Mirabella, S, Morelli, Mc, Nicolini, D, Petruccelli, S, Regalia, E, Reggiani, P, Roselli, S, Zamboni, F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::295e255cfae5e13e9e831d4f317b9361
https://hdl.handle.net/11380/1249427

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Autor: Pegbeliver, Study Group, Colombo, M, Facchetti, F, Massetto, B, Regep, L, Iannacone, C, Giuberti, T, Fargion, S, Farci, P, Boninsegna, S, Di Marco, V, Fasano, M, Sagnelli, E, Di Costanzo, Gg, Viganò, M, Lampertico, P, Andreone, P, Riili, A, Scuteri, A, Cursaro, C, Andriulli, A, Niro, Ga, Angarano, G, Santantonio, Ta, Palattella, Ms, Brunetto, MAURIZIA ROSSANA, Colombatto, P, Coco, B, Ciccorossi, P, Oliveri, F, Sacco, R, Bruno, S, Bollani, S, Chiesa, A, Carosi, G, Baiguera, C, Rossi, S, Zaltron, S, Puoti, M, Cozzolongo, R, Giannuzzi, V, Craxì, A, Calvaruso, V, Venezia, G, Lanza, Ag, Di Perri, G, Cariti, G, Mollaretti, O, De Blasi, T, Kulmiye, C, Rostagno, R, Lai, Me, Serra, G, Chessa, L, Balestrieri, C, Cauli, C, Fargion, Sr, Bertelli, C, Fatta, E, Fattovich, G, Pasino, M, Zanni, S, Olivari, N, Zagni, I, Ferrari, C, Schivazappa, S, Laccabue, D, Penna, A, Gaeta, G, Stanzione, M, Stornaiuolo, G, Martines, D, Raimondo, G, Caccamo, G, Squadrito, G, Isgrò, G, Rizzetto, M, Lagget, M, Carenzi, S, Ruggiero, G, Marrone, A, Messina, V, Di Caprio, Du, Selva, V, Toniutto, P.

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whethe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dee5413b7f9c6cb0e810d621c76720f
http://hdl.handle.net/11568/844307

Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.

Autor: Di Costanzo GG, De Luca M, Tritto G, Lampasi F, Addario L, Lanza AG, Tartaglione MT, Picciotto FP, Ascione A

Publikováno v: European Journal of Gastroenterology & Hepatology; 2008 Jul, Vol. 20 Issue 7, p674-679, 6p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.